Abstracts tagged "myositis and synthetase syndrome"

Abstract Number: 1340 • 2018 ACR/ARHP Annual Meeting
Anti-Aminoacyl-tRNA-Synthetase Antibodies Which Are Positive By ELISA but Negative By RNA-Immunoprecipitation Suggest Different Antigen Recognition and Clinical Relevance Different from Typical Anti-Synthetase Syndrome
Tsuneo Sasai¹, Ran Nakashima², Yuki Ishikawa³, Takuya Isayama⁴ and Tsuneyo Mimori², ¹Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Japan, Kyoto, Japan, ²Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ³One Joslin Place, Joslin Diabetes Center, Harvard Medical School, Boston, MA, ⁴Medical & Biological Laboratories CO.,LTD., Nagoya, Japan
Background/Purpose: Anti-aminoacyl-tRNA-synthetase (ARS) antibodies are myositis specific autoantibodies and associated with common clinical characteristics called anti-synthetase syndrome (ASS). Recently anti-ARS detecting enzyme-linked immunosorbent assay (ELISA)…
Abstract Number: 1011 • 2016 ACR/ARHP Annual Meeting
Correlations Between B Cell Epitope Specificity and Clinical Features in Patients with Jo-1 Antibodies and the Anti-Synthetase Syndrome
Joseph LaConti¹, Fanny Kippelen², Rohit Aggarwal³ and Dana P. Ascherman⁴, ¹Division of Rheumatology, University of Miami Miller School of Medicine, Miami, FL, ²Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, ³Department of Medicine / Rheumtology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL
Correlations Between B Cell Epitope Specificity and Clinical Features in Patients with Jo-1 Antibodies and the Anti-Synthetase Syndrome Background/Purpose: Idiopathic inflammatory myopathy (IIM) is an…
Abstract Number: 1272 • 2014 ACR/ARHP Annual Meeting
Myositis-Specific and Myositis Associated Autoantibodies in Indian Patients with Inflammatory Myositis
Puja Srivastava, Ramnath Misra, Able Lawrence, Amita Aggarwal and Vikas Agarwal, Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose Recently, idiopathic inflammatory myositis (IIM) has been categorised into distinct subsets based on myositis specific autoantibodies (MSA) and myositis associated autoantibodies (MAA). However, there is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].